Summary by Moomoo AI
Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in sales and operating profit for the first nine months of 2024. Sales rose by 23% in Danish kroner and 24% at constant exchange rates (CER) to DKK 204.7 billion, while operating profit grew by 21% in Danish kroner and 22% at CER to DKK 91.6 billion. The growth was primarily driven by the Diabetes and Obesity care segment, with GLP-1 diabetes sales increasing by 25% in Danish kroner and Obesity care growing by 44% to DKK 43.7 billion. North America Operations saw a 31% increase in sales, with the US market contributing significantly to this growth. The company also completed several clinical trials, including the phase 2a trial with monlunabant in obesity, and announced positive results from the...Show More
